Precision medicine may have transitioned from buzzword to reality, but that doesn’t mean innovations in the field have stagnated – and, of course, the question of patient access remains ever-present. This month our writers analyse these trends in three features on p20, p22 and p24.
October played host to World Mental Health Day, highlighting an issue that is becoming front-and-centre of the industry’s objectives. As well as looking at the potential next generation of depression treatments on p31 we also ask how pharma can look after their employees’ own mental health on p28.
Elsewhere, we take a look at how pharma and CROs can optimise their relationship (p34), how organs on chips could change clinical trials (p38) and what the introduction of biosimilar adalimumab, the world’s biggest-selling drug, could mean for the NHS (p16).
I hope you enjoy the issue.
